203 related articles for article (PubMed ID: 31181320)
1. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Wang W; Qin JJ; Voruganti S; Nijampatnam B; Velu SE; Ruan KH; Hu M; Zhou J; Zhang R
Cancer Res; 2018 Oct; 78(19):5656-5667. PubMed ID: 30217928
[TBL] [Abstract][Full Text] [Related]
3. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Zhang X; Zhang Z; Cheng J; Li M; Wang W; Xu W; Wang H; Zhang R
J Biol Chem; 2012 Aug; 287(36):30468-76. PubMed ID: 22787160
[TBL] [Abstract][Full Text] [Related]
6. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W; Zafar A; Rajaei M; Zhang R
Cells; 2020 May; 9(5):. PubMed ID: 32397368
[TBL] [Abstract][Full Text] [Related]
7. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
8. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
9. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
10. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
11. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
[TBL] [Abstract][Full Text] [Related]
12. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
13. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
14. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR.
Jiang D; Cho WC; Li Z; Xu X; Qu Y; Jiang Z; Guo L; Xu G
Biomed Pharmacother; 2017 Dec; 96():535-544. PubMed ID: 29032337
[TBL] [Abstract][Full Text] [Related]
15. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
16. [ShRNA-mediated silencing of MDM2 inhibits growth of HepG2 hepatocellular carcinoma cells xenografted in nude mice].
Zhao YY; Li YG; Sun YJ; Liu HP; Yang ZC; Zhang DD; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):213-7. PubMed ID: 23967744
[TBL] [Abstract][Full Text] [Related]
17. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development.
Xie X; Wang X; Liao W; Fei R; Wu N; Cong X; Chen Q; Wei L; Wang Y; Chen H
J Exp Clin Cancer Res; 2018 Feb; 37(1):28. PubMed ID: 29439719
[TBL] [Abstract][Full Text] [Related]
18. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
19. MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin.
Lu S; Zhou W; Wei H; He L; Li L
Dig Dis Sci; 2015 Dec; 60(12):3681-90. PubMed ID: 26280083
[TBL] [Abstract][Full Text] [Related]
20. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
